Amino quinazolines as kinase inhibitors
AssigneeGlaxoSmithKline Intellectual Property Development Limit
InventorsAdam K. CHARNLEY, Xiaoyang DONG
Life of this patent
Estimating the term…
Abstract
Disclosed are compounds having the formula: wherein R1, R2, R3, and Z are as defined herein, and methods of making and using the same.
Claims14
A compound which is 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol having the structure of
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising the compound of 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol having the structure of
- or a pharmaceutically acceptable salt thereof,
- and a pharmaceutically acceptable excipient.
A method of treating a disease mediated by RIP2 kinase comprising administering to a human in need thereof a therapeutically effective amount of the compound of 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol having the structure of
- or a pharmaceutically acceptable salt thereof,
- wherein the disease is selected from the group consisting of uveitis, dermatitis, acute lung injury, type 2 diabetes mellitus, arthritis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, early-onset inflammatory bowel disease, extraintestinal inflammatory bowel disease, prevention of ischemia reperfusion injury in solid organ transplant, non-alcohol steatohepatitis, autoimmune hepatitis, asthma, systemic lupus erythematosus, multiple sclerosis, sarcoidosis, Blau syndrome/early-onset sarcoidosis, Wegner's granulomatosis, and interstitial pulmonary disease.
A method of treating a disease selected from the group consisting of Blau Syndrome, ulcerative colitis, Crohn's disease, and rheumatoid arthritis comprising administering the compound of 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol to a human in need thereof.
Dependencies are inferred from the claim text.